PROCEPT BioRobotics Corporation (PRCT) Stock
PRCT Key Statistics
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
CEO: Larry L. Wood. Company website
PRCT — Frequently Asked Questions
What is the PRCT stock price today?
PROCEPT BioRobotics Corporation (PRCT) trades at $19.30, down 0.87% on the day, as of Sep 20, 2026 14:56 UTC.
What is PROCEPT BioRobotics Corporation's market cap?
PROCEPT BioRobotics Corporation has a market capitalisation of $1.10B, calculated from the live PRCT share price and shares outstanding.
What is the P/E ratio of PRCT?
PRCT has no meaningful price-to-earnings ratio: PROCEPT BioRobotics Corporation lost $1.94 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does PROCEPT BioRobotics Corporation make?
PROCEPT BioRobotics Corporation generated revenue of $337.34M over the trailing twelve months, which puts the stock at 3.26 times sales.
What is the 52-week range for PRCT?
PRCT has traded between $16.67 and $40.10 over the past 52 weeks, and the last price is 51.9% below that high.
Is PROCEPT BioRobotics Corporation profitable?
No. PROCEPT BioRobotics Corporation is loss-making, with a net margin of -32.54% over the trailing twelve months.
What is the analyst price target for PRCT?
Wall Street analysts rate PRCT Buy, with an average price target of $22.13, 14.7% above the current price.
What sector is PROCEPT BioRobotics Corporation in?
PROCEPT BioRobotics Corporation is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Who is the CEO of PROCEPT BioRobotics Corporation?
Larry L. Wood is the chief executive of PROCEPT BioRobotics Corporation, which employs 888 people.
Where can I track PRCT in real time?
QFI Terminal shows PRCT with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See PRCT live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open PRCT in Terminal See plans